Associated tags: Diabetes, Pod, Corporation, Insulin pump, Health, Medical Devices, General Health, Eastern Time Zone, Pharmaceutical industry, Biotechnology, Medical device, Health Technology
Locations: IRELAND, EUROPEAN UNION, CANADA, SAN FRANCISCO, LONDON, CALIFORNIA, BERLIN, ENGLAND, WALES, AUSTRALIA, UNITED STATES, NORTH AMERICA, MASSACHUSETTS, GE, LATIN AMERICA, UTAH, EUROPE, WASHINGTON
Women,
Other Manufacturing,
Consumer Electronics,
Seniors,
Technology,
Diabetes,
Men,
General Health,
Family,
Manufacturing,
Consumer,
Teens,
Parenting,
Medical Devices,
Children,
Baby,
Maternity,
Health Technology,
LGBTQ+,
Other Technology,
Health,
Wearables,
Mobile Technology,
Corporation,
Eastern Time Zone Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2024 on May 9, 2024 after the close of the financial markets.
Key Points:
- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2024 on May 9, 2024 after the close of the financial markets.
- In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).
- The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com , “Events and Presentations,” and will be archived for future replay.
- You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2109 for international callers, passcode is 5904836.
Retrieved on:
Wednesday, March 20, 2024
Diabetes,
Health,
Medical Devices,
D.C,
Growth,
American University,
Mentorship,
CFO,
Corporation,
Pitney Bowes,
Controller,
Treasurer,
Audit committee,
Interim management,
Interim,
Multimedia,
Management Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Ana Maria Chadwick has been appointed Executive Vice President, Chief Financial Officer and Treasurer, effective April 22, 2024.
Key Points:
- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Ana Maria Chadwick has been appointed Executive Vice President, Chief Financial Officer and Treasurer, effective April 22, 2024.
- View the full release here: https://www.businesswire.com/news/home/20240320426712/en/
“We are thrilled to welcome Ana to Insulet,” said Jim Hollingshead, President and Chief Executive Officer.
- Ana is known for her insight, intellectual agility, and compelling and collaborative leadership.
- Over the span of her career, she has led large and dynamic finance teams, overseeing financial reporting, and driving financial and operational efficiencies in the U.S., Latin America, and Europe.
Research,
General Health,
Technology,
Medical Devices,
Other Manufacturing,
Health Technology,
Clinical Trials,
Science,
Biotechnology,
Wearables,
Mobile Technology,
Health,
Diabetes,
Manufacturing,
TIR,
Dexcom,
CGM,
Doctor of Philosophy,
Randomized controlled trial,
MD,
Treatment,
Medical director,
G6,
AID,
Intervention,
Conference,
ATTD,
Safety,
Hypoglycemia,
Control,
RCT,
T1D,
Corporation,
DKA,
Body mass index,
Treatment and control groups,
Pharmaceutical industry The OP5-003 Trial results were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy.
Key Points:
- The OP5-003 Trial results were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy.
- "Omnipod 5 continues to demonstrate impressive clinical outcomes for people with type 1 diabetes,” said Professor Renard.
- The control group (n=62) continued to use their usual insulin pump with a Dexcom G6 CGM, while the intervention group (n=132) used Omnipod 5 with Dexcom G6.
- In conclusion, this multi-national, RCT data demonstrates the superiority of the Omnipod 5 AID System compared to standard pump therapy with CGM and indicates that it should be offered as a first-line therapy for adults with type 1 diabetes.
Health Technology,
Diabetes,
Manufacturing,
Technology,
Pharmaceutical,
Other Consumer,
General Health,
Medical Devices,
Clinical Trials,
Wearables,
Mobile Technology,
Other Manufacturing,
Science,
Consumer,
Health,
Research,
Real-World Evidence,
Cloud,
OBE,
Adolescence,
Doctor of Philosophy,
Treatment,
Medical director,
Database,
University,
Hypoglycemia,
Associate,
AID,
University of Liverpool,
Standard of care,
Data,
Therapy,
Insulin,
Convention,
Randomized controlled trial,
CGM,
Pathway,
Use,
Conference,
MDI,
Automation,
Endocrinology,
MD,
DASH,
ATTD,
Medicare,
University of Edinburgh,
Edge Hill University,
Corporation,
Chairperson,
Medical device “We are thrilled to unveil the results of our inaugural randomized controlled trial with groundbreaking insights from international Omnipod 5 users,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director.
Key Points:
- “We are thrilled to unveil the results of our inaugural randomized controlled trial with groundbreaking insights from international Omnipod 5 users,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director.
- It is the first Omnipod 5 randomized controlled trial to date, and the first time the system has been evaluated in participants living outside of the United States.
- This presentation will take place on Thursday, March 7 at 12:00 p.m. CET and Friday, March 8 at 10:30 a.m. CET.
- Insulet representatives will be available to provide Omnipod product demonstrations to conference attendees, offering healthcare professionals the chance to experience Omnipod DASH and Omnipod 5 first-hand.
Retrieved on:
Thursday, February 22, 2024
Medical Devices,
Health,
Diabetes,
Manufacturing,
Health Technology,
Other Manufacturing,
ERP,
Pharmacy,
Developed country,
Investment,
Adjustment,
MDC,
Therapy,
Automated insulin delivery system,
Eastern Time Zone,
Corporation,
Prescription,
Security (finance) Adjusted gross margin1 of 70.7%, up 620 basis points, excludes income of $0.9 million associated with the voluntary MDC notices issued in 2022.
Key Points:
- Adjusted gross margin1 of 70.7%, up 620 basis points, excludes income of $0.9 million associated with the voluntary MDC notices issued in 2022.
- Revenue growth ranges by product line are:
For the quarter ending March 31, 2024, the Company expects revenue growth of 17% to 20%.
- Insulet will host a conference call at 4:30 p.m. (Eastern Time) on February 22, 2024 to discuss the financial results and outlook.
- The live call may also be accessed by dialing (888) 770-7129 for domestic callers or (929) 203-2109 for international callers, passcode 5904836.
Retrieved on:
Tuesday, February 13, 2024
Women,
Manufacturing,
Seniors,
Teens,
Parenting,
Men,
Other Technology,
Children,
Baby,
Maternity,
Family,
Medical Devices,
Consumer,
Consumer Electronics,
LGBTQ+,
Technology,
General Health,
Diabetes,
Health,
Other Manufacturing,
Eastern Time Zone,
Corporation,
Webcast,
Conference Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at The Raymond James & Associates 45th Annual Institutional Investors Conference in Orlando on Tuesday, March 5, 2024 at 11:35 a.m. (Eastern Time).
Key Points:
- Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at The Raymond James & Associates 45th Annual Institutional Investors Conference in Orlando on Tuesday, March 5, 2024 at 11:35 a.m. (Eastern Time).
- To listen to the live audio webcast of the presentation, please visit investors.insulet.com/events .
- A replay of the webcast will also be available following the event.
Retrieved on:
Wednesday, February 7, 2024
Health,
Medical Devices,
Other Consumer,
Consumer,
Diabetes,
Health Technology,
Managed Care,
Multimedia,
Senior,
CGM,
International,
Glucose,
Ageing,
Pod,
System,
CE,
Corporation,
Medical device Key Points:
- View the full release here: https://www.businesswire.com/news/home/20240207666366/en/
The Omnipod 5 Automated Insulin Delivery System with the Abbott FreeStyle Libre 2 Plus CGM sensor (Photo: Business Wire)
“The addition of the Abbott FreeStyle Libre 2 Plus sensor to our CGM compatibility expands accessibility of Omnipod 5, which has been a priority for Insulet since the system launched in 2022,” said Patrick Crannell, Senior Vice President and International General Manager of Insulet.
- The Omnipod 5 System consists of the tubeless Pod enhanced with SmartAdjust™ Technology and the Omnipod 5 Controller with its integrated Smartbolus Calculator.
- The Pod’s SmartAdjust technology receives a CGM value and trend and predicts where glucose will be 60 minutes into the future.
- Insulet expects Omnipod 5 integration with the Abbott FreeStyle Libre 2 Plus sensor to be available first in the United Kingdom and Netherlands in a phased launch in the first half of 2024, with additional markets to follow.
Retrieved on:
Thursday, January 18, 2024
Medical Supplies,
Health,
Medical Devices,
Diabetes,
Health Technology,
General Health,
Biotechnology,
Corporation,
Medical device,
Alcon,
Business administration,
University,
Santa Clara University,
HPE,
Johnson & Johnson,
General Electric,
Hewlett Packard Enterprise,
Management In addition, the Company announced Shacey Petrovic and Corinne Nevinny will retire from the Board during the Company’s 2024 Annual Meeting in May.
Key Points:
- In addition, the Company announced Shacey Petrovic and Corinne Nevinny will retire from the Board during the Company’s 2024 Annual Meeting in May.
- “We are excited to welcome Flavia and Tim to the Insulet Board,” said Timothy Scannell, Chairman of Insulet’s Board of Directors.
- “They are both highly respected leaders who have had distinguished careers and critical leadership roles in prominent corporations.
- She joined Charles River in 2022 as Corporate Executive Vice President and Chief Financial Officer where she leads the Finance and Procurement Functions.
Retrieved on:
Thursday, January 11, 2024
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2023 on February 22, 2024 after the close of the financial markets.
Key Points:
- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2023 on February 22, 2024 after the close of the financial markets.
- In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).
- The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com , “Events and Presentations,” and will be archived for future replay.
- You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2109 for international callers, passcode is 5904836.
Retrieved on:
Tuesday, November 28, 2023
Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at two upcoming investor conferences (all Eastern Time):
Key Points:
- Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at two upcoming investor conferences (all Eastern Time):
The Nasdaq 29th Investor Conference in London on Tuesday, December 5, 2023 at 10:00 a.m.
- The J.P. Morgan Annual Healthcare Conference in San Francisco on Tuesday, January 9, 2024 at 12:45 p.m.
To listen to the live audio webcasts of the presentations, please visit investors.insulet.com/events .
- Replays of the webcasts will also be available following the event.
